FIGO Stage I endometrial carcinoma: evaluation of lung metastases and follow-up

Purpose: The aim of our study was to evaluate the incidence of lung metastases in the follow-up of women submitted to surgery for endometrial carcinoma, in particular for FIGO Stage I which is the lowest risk stage for this metastatic site. Methods: The study was conducted on 210 patients affected by FIGO Stage I endometrial cancer in the years 1990 to 2005 distributed as follows: 35 patients with Stage IA (limited to the endometrium), 150 patients with Stage 113 (invasion up to and including half the myometrial thickness), 25 patients with Stage IC (invasion greater than half the myometrial thickness). They underwent follow-up. Results: Only one patient out of the group studied has developed lung metastasis six years after surgery. She was staged as FIGO IB (T1b Mx G1). Conclusion: We are still following the cases and evaluating the biological behavior of this specific endometrial carcinoma and its reaction to further therapies. We are also looking for possible clinical characteristics in disagreement with those reported in the literature, which would thus make-it necessary to reconsider the prognosis and therapy of this stage of disease.

Endometrial cancer; Lung metastasis; Follow-up; Lung metastasis therapy

[1] Gastaldi A., Bianchi U.A. et al.: “Surgical staging in endometrial cancer”. Proceedings of the International Meeting of Gynecologic Oncology, SOG, Padua, 1985.

[2] Creasman W.T.: “FIGO stage 1988 revision”. Gynecol. Oncol.,1989, 35, 125.

[3] Kilgore L.C., Partridge E.E., Alvarez R.D., Austin J.M., Shingleton H.M., Moojin F. et al.: “Adenocarcinoma of the endometrium: survival comparisons of the patients with and without pelvic node sampling”. Gynecol. Oncol., 1995, 56, 29.

[4] Connel P.P., Rotmensch J., Waggoner S., Mundt A.J.: “Significance of adnexal involvement in endometrial carcinoma”. Gynecol. Oncol., 2003, 74, 74.

[5] Lutman C.V., Havrilesky L.J., Cragun J.M., Secord A.A., Calingaert B., Berchuck A. et al.: “Pelvic lymph node count is an important prognostic variable for FIGO Stage I and II endometrial carcinoma with high-risk histology”. Gynecol. Oncol. 2006 Jan 5; [Epub ahead of print].

[6] Parazzini F., La Vecchia C., Bocciolone L., Franceschi S.: “The epidemiology of endometrial cancer”. Gynecol. Oncol., 1991, 41, 1.

[7] Jemal A., Murray T., Ward E. et al.: “Cancer statics 2005”. Cancer J. Clin., 2005, 55, 10.

[8] Purdie D.M., Green E.: “Epidemiology of endometrial cancer”. Best Pract. Res. Clin. Obstet. Gynecol., 2001, 15, 341.

[9] Amant F., Moerman P., Neven P., Timmerman D., Van Limbergen E., Vergote I.: “Endometrial cancer”. Lancet, 2005, 366, 491.

[10] Otsuka I., Ono I., Akamatsu H., Sunamori M., Aso T.: “Pulmonary metastasis from endometrial carcinoma”. Int. J. Gynecol. Cancer, 2002, 12, 208.

[11] Santin A.D., Bellone S., O'Brien T.J., Pecorelli S., Cannon M.J., Roman J.J.: “Current treatment options for endometrial cancer”. Expert Rev. Anticancer Ther., 2004, 4, 679.

[12] Leijon T., Rosenberg P., Boeryd B.: “Total abdominal hysterectomy and bilateral salpingo-oophorectomy. A sufficient treatment for patients with low risk endometrial carcinoma”. Int. J. Gynecol. Oncol., 1997, 7, 376.

[13] Zorlu C.G., Simsek T., Ari E.S.: “Laparoscopy or laparotomy for the management of endometrial cancer”. JSLS, 2005, 9, 442.

[14] Creutzberg C.L., van Putten W.L., Koper P.C. et al.: “Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma”. Lancet, 2000, 355, 1404.

[15] Cengiz M., Singh A.K., Grigsby P.W.: “Postoperative vaginal brachytherapy alone is the treatment of choice for grade 1-2, stage IC endometrial cancer”. Int. J. Gynecol. Cancer, 2005, 15, 926.

[16] Chen S.S.: “Operative treatment in Stage I endometrial carcinoma with deep myometrial invasion and or grade 3 tumor surgically limited to the corpus uteri”. Cancer, 2000, 63, 1834.

[17] Mangioni C., DePalo G., DelVecchio M.: “Surgical pathologic staging in apparent Stage I endometrial cancer”. Int. J. Gynecol. Cancer, 2003, 3, 373.

[18] Patterson E. et al.: “Management of stage I carcinoma of the uterus”. Obstet. Gynecol., 1992, 59, 755.

[19] Kew F.M., Cruickshank D.J.: “Routine follow up after treatment for a gynaecological cancer: a survey of practice”. Int. J. Gynecol. Cancer, 2006, 16, 380.

[20] Bouros D., Papadakis K., Siafakas N., Fuller A.F. Jr.: “Patterns of pulmonary metastasis from uterine cancer”. Oncology, 1996, 53, 360.

[21] Bouros D., Papadakis K., Siafakas N., Fuller A.F. Jr.: “Natural history of patients with pulmonary metastases from uterine cancer”. Cancer, 1996, 78, 441.

[22] Barakat R.R., Bundy B.N., Spirtos N.M., Bell J.G., Mannel R.S.: “A prospective randomized double-blind trial of estrogen replacement therapy vs placebo in women with Stage I or II endometrial cancer: a GOG study”. Gynecol. Oncol., 2004, 78 (abstract 1).

[23] Agboola O., Grunfeld E., Coyle D., Perry G.: “Cost and benefits of routine follow-up after curative treatment for endometrial cancer. CMAJ, 1997, 157, 879.

[24] Morice P., Levy-Piedbois C., Ajaj S., Pautier P., Haie-Neder C., Lhomme C. et al.: “Value and cost evaluation of routine follow up for patients with clinical Stage I/II endometrial cancer”. Eur. J. Cancer, 2001, 37, 985.

[25] Morrow C.P., Bundy B.N., Homesley H.D. et al.: “Doxorubicin as an adjuvant folling surgery and radiation therapy in patients with high-risk endometrial carcinoma, Stage I and occult Stage II: a GOG study”. Gynecol. Oncol., 1990, 36, 166.

[26] Seltzer V., Vogl S., Kaplan B.: “Adriamicin and cisdiamminedichloroplatinum in the treatment of metastatic endometrial adenocarcinoma”. Gynecol. Oncol., 1984, 19, 308.

[27] Fleming G., Brunetto V., Cella D., Look K.Y., Reid G.C., Munkarah A.R. et al.: “Phase III trial of doxorubicin plun cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a GOG study”. J. Clin. Oncol., 2004, 22, 2159.

[28] Hoskins P., Swerton K., Pike J., Wong F., Lee N.: “Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study”. J. Clin. Oncol., 2001, 19, 4048.

[29] Campagnutta E., Giorda G., De Piero G. et al.: “Surgical treatment of recurrent endometrial carcinoma”. Cancer, 2004, 100, 89.